Rayeiris Maduro Rondon
πŸ’Ž π™π™π™š π™žπ™’π™₯π™€π™§π™©π™–π™£π™˜π™š 𝙀𝙛 π™›π™žπ™£π™™π™žπ™£π™œ π™œπ™šπ™’π™¨ π™—π™šπ™›π™€π™§π™š π™©π™π™š 𝙛𝙖𝙙𝙨 πŸ’Ž 6 months ago I was doing personal research for the best products in the market regards skincare and anti-aging. After reviewing expert dermatologists and clinical results, I came across Medik8. I bought a bunch of serums, and wow, after just one day, I noticed my skin renewed. This product works, now I need the stocks too. It was a private company from the UK with not much information about it, and the matter was closed to me… Until yesterday, I received the news, and guess what, $OR.PA (LOreal SA) bought Medik8 for a stratospheric amount of 1,1 billion. This shows a clear overpay, when Medik8 only has 77 million in revenue. We know with the acquisition, L'OrΓ©al can position Medik8 as a pretty well-known brand, but paying 14 times sales for a brand worth just for a technology of retinoids which isn’t exclusive to them and with pharmaceutical options for a quarter of the price. I believe L'OrΓ©al is a fantastic brand, and I’ve analyzed it several times to find a reason to overpay for the stock. But still buying Medik8 and now being a consumer of the brand, I don’t justify paying 31x earnings for L'OrΓ©al due to the growing rates. Here is my analysis of L'OrΓ©al if you want to have a look: www.etoro.com/news-and-analysis/in-depth-analysis/loreal-the-number-one-in-the-beauty-business-world/ Got a stock on your watchlist that seems overpriced… or under the radar? Drop it below πŸ‘‡πŸΌπŸ‘‡πŸΌ $SPX500 (SPX500 Index (Non Expiry)) $NSDQ100 (NASDAQ100 Index (Non Expiry)) $ELF (elf Beauty Inc)
Like CommentShare
1 reply
2 replies
2 replies
null
.